Alliancebernstein L.P. Has $11.17 Million Stake in Catalent Inc (CTLT)
Alliancebernstein L.P. boosted its holdings in Catalent Inc (NYSE:CTLT) by 64.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 245,219 shares of the company’s stock after acquiring an additional 96,400 shares during the period. Alliancebernstein L.P.’s holdings in Catalent were worth $11,170,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also bought and sold shares of CTLT. Nelson Van Denburg & Campbell Wealth Management Group LLC bought a new stake in Catalent in the 2nd quarter valued at $145,000. Moneta Group Investment Advisors LLC raised its stake in Catalent by 105.0% in the 2nd quarter. Moneta Group Investment Advisors LLC now owns 3,515 shares of the company’s stock valued at $147,000 after acquiring an additional 1,800 shares during the period. CIBC Asset Management Inc bought a new stake in Catalent in the 3rd quarter valued at $217,000. Rehmann Capital Advisory Group raised its stake in Catalent by 1,895.9% in the 2nd quarter. Rehmann Capital Advisory Group now owns 5,309 shares of the company’s stock valued at $222,000 after acquiring an additional 5,043 shares during the period. Finally, Chicago Equity Partners LLC bought a new stake in Catalent in the 3rd quarter valued at $237,000. Institutional investors and hedge funds own 96.77% of the company’s stock.
A number of brokerages have commented on CTLT. Royal Bank of Canada set a $45.00 price objective on Catalent and gave the company a “buy” rating in a report on Friday, November 16th. ValuEngine raised Catalent from a “hold” rating to a “buy” rating in a report on Monday, November 12th. Morgan Stanley set a $46.00 price objective on Catalent and gave the company a “buy” rating in a report on Monday, December 3rd. TheStreet lowered Catalent from a “b-” rating to a “c+” rating in a report on Wednesday, November 7th. Finally, Zacks Investment Research raised Catalent from a “sell” rating to a “hold” rating in a report on Monday, October 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $48.00.
CTLT opened at $36.32 on Friday. The firm has a market cap of $5.53 billion, a PE ratio of 22.84, a P/E/G ratio of 2.38 and a beta of 1.44. Catalent Inc has a 52-week low of $34.24 and a 52-week high of $47.87. The company has a current ratio of 2.05, a quick ratio of 1.61 and a debt-to-equity ratio of 1.44.
Catalent (NYSE:CTLT) last released its earnings results on Tuesday, November 6th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.04. The company had revenue of $551.80 million for the quarter, compared to analyst estimates of $582.44 million. Catalent had a return on equity of 19.13% and a net margin of 2.65%. Catalent’s quarterly revenue was up 1.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.21 EPS. Equities analysts forecast that Catalent Inc will post 1.63 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Alliancebernstein L.P. Has $11.17 Million Stake in Catalent Inc (CTLT)” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2018/12/08/alliancebernstein-l-p-has-11-17-million-stake-in-catalent-inc-ctlt.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Further Reading: Understanding the different types of bonds
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.